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Case report
Phosphate is essential in regulating human metabolic processes, and severe 
hypophosphatemia can induce neurologic and hematological complications and 
result in respiratory failure and cardiac dysfunction. Therefore, correction of severe 
hypophosphatemia can be pivotal in the management of diabetic ketoacidosis 
(DKA). We report the case of a 14-year-old female who was diagnosed with type 1 
diabetes and referred to our institute for treatment of DKA. Although the patient 
received fluid and continuous insulin administration according to the current DKA 
treatment protocol, generalized tonic seizures and cardiac arrest developed. After 
cardiopulmonary resuscitation, the patient recovered and was stable. Within 16 
hours after DKA treatment, the patient developed respiratory failure with severe 
hypophosphatemia that required mechanical ventilation. Concurrent neurologic 
evaluation revealed no specific abnormalities. The patient recovered without 
any complications after correcting the hypophosphatemia. We suggest vigilant 
monitoring of the phosphate level in DKA patients and active replacement when 
required. 
Keywords: Diabetic ketoacidosis, Hypophosphatemia, Respiratory failure
©2018 Annals of Pediatric Endocrinology & Metabolism
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any 




Diabetic ketoacidosis (DKA) is a life-threatening acute complication of diabetes mellitus. 
DKA is characterized by hyperglycemia, metabolic acidosis, ketonemia, and ketonuria, which 
are caused by insulin deficiency and/or relatively reduced insulin effectiveness. The severity 
of DKA is categorized as mild to severe by the degree of metabolic acidosis, and morbidity 
and mortality are markedly increased in severe DKA.1) Among causes of morbidity and 
mortality in DKA, cerebral edema is the major cause, and rarely, many factors are included 
such as hypoglycemia, respiratory complications, sepsis, peripheral venous thrombosis, acute 
renal failure, acute pancreatitis, and other central nervous system complications. Electrolyte 
imbalance also frequently develops in DKA patients as low levels of the anabolic hormone 
insulin promote catabolic processes. Hyperglycemia-induced osmotic diuresis increases 
loss of electrolytes and minerals. Metabolic acidosis causes shifts of potassium, phosphorus, 
and magnesium from the intracellular to extracellular compartment. Extracellular fluid 
volume expansion and correction of acidosis during DKA treatment also reduce serum ion 
concentrations. Most patients with DKA require electrolyte replacement for imbalances. 
Most cases of hypophosphatemia during DKA treatment are mild and self-limited. Routine 
phosphate supplementation has shown no clinical benefit.2,3) Nonetheless, supplementation 
should be initiated if  hypophosphatemia is severe and associated with symptoms of 
metabolic encephalopathy, impaired myocardial contractibility, respiratory failure, dysphagia, 
ileus, hematologic abnormalities, and rhabdomyolysis.4,5) We report here a case of severe 
hypophosphatemia associated with acute respiratory failure in an adolescent during DKA 
treatment.
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Case report
A 14-year-old female with symptoms of nausea, vomiting, 
and abdominal pain for 3 days was admitted to the local clinic 
with the diagnosis of acute viral gastroenteritis. Laboratory 
results showing hyperglycemia (glucose, 500 mg/dL) and 
ketonuria strongly indicated DKA. The patient was transferred 
to our emergency unit because of worsening mental status 
despite initiation of therapy with intravenous fluid and short-
acting insulin. The patient's medical history was unremarkable 
(her mother had type 2 diabetes mellitus). On admission, the 
patient was lethargic, severely dehydrated, and drowsy (Glasgow 
Coma Scale [GCS, eye-verbal-motor]=14 [3-5-6]). Vital signs 
indicated tachycardia (124 beats/min), tachypnea (40 breaths/
min), and hypothermia (35℃). Blood pressure was in the 
normal range (106/56 mmHg), body weight had decreased by 
1.7 kg in the previous month to 48 kg (25th–50th percentile), 
and body mass index was 20 kg/m2 (50th–75th percentile). 
Chest and abdominal x-rays showed no specific abnormalities. 
Initial venous blood gas analysis indicated metabolic acidosis 
(pH, 6.92; PCO2, 27 mmHg; PO2, 57 mmHg; HCO3, 5.6 mmol/
L). Serum chemistry and electrolyte tests revealed 569 mg/dL 
glucose, 133 mmol/L corrected sodium, 3.2 mmol/L potassium, 
8.5 mg/dL corrected calcium, 2.1 mg/dL phosphate, 25.9 mg/
dL blood urea nitrogen, 0.57 mg/dL creatinine, and 0.6 mmol/L 
lactate. Urinalysis indicated the presence of ketones and glucose. 
Endocrinologic assessments showed 0.26 ng/mL C-peptide 
(normal range, 0.6–2.3 ng/mL) and 15.7% glycosylated 
hemoglobin. Antiglutamic acid decarboxylase was positive (1.72 
U/mL; range, 0–1 U/mL), whereas anti-islet cell and anti-insulin 
antibodies were negative. These findings indicated a diagnosis 
of type 1 diabetes and severe DKA. The main metabolic data 
during  hospitalization are shown in Table 1. Fluid (0.45% 
saline) and continuous intravenous insulin infusion therapy 
were initiated at a rate of 0.05 unit/kg/hr immediately according 
to DKA treatment protocol.5) Hourly neurological evaluations 
were performed for signs of cerebral edema. Although the 
patient remained drowsy, signs of cerebral edema were not 
evident. The patient suffered a <1 min generalized tonic seizure 
at 4 hours postadmission that was followed by bradycardia 
and cardiopulmonary arrest. External cardiac massage was 
initiated, followed by one epinephrine injection. Spontaneous 
circulation resumed after 6 minutes of  cardiopulmonary 
resuscitation. Laboratory data after return of spontaneous 
circulation showed metabolic acidosis and hypophosphatemia 
(pH, 7.05; PCO2, 23.6 mmHg; PO2, 181 mmHg; HCO3, 6.7 
mmol/L; glucose, 517 mg/dL; corrected sodium, 136 mmol/
L; potassium, 3.2 mmol/L; corrected calcium, 8.8 mg/dL; 
phosphate, 1.2 mg/dL). The patient received K2HPO4 and KCl 
to achieve 1.9 mEq/kg/day of phosphorus after the cardiac 
arrest. A brain computed tomographic (CT) scan showed no 
brain edema or intracranial pathology. Dexamethasone and 
mannitol were prescribed for prevention of brain edema and 
the patient was admitted to the intensive care unit. Although 
the patient remained drowsy (GCS=14 [3-5-6]), vital signs 
were stable. At 16 hours after initiation of DKA treatment, the 
patient became stuporous (GCS=9 [2-2-5]) with shallow, weak, 
and slow respiration that necessitated endotracheal intubation. 
Blood tests at this time revealed respiratory acidosis and severe 
hypophosphatemia (pH, 6.80; PCO2, 92.9 mmHg; PO2, 160.3 
mmHg; HCO3, 14.6 mmol/L; glucose, 375 mg/dL; corrected 
sodium, 142 mmol/L; potassium, 2.8 mmol/L; phosphate, 
0.4 mg/dL; lactate, 0.6 mmol/L). Phosphate replacement was 
increased to achieve a 3.8 mEq/kg/day phosphorus rate. A 
repeat brain CT imaging study showed no specific findings. The 
patient's electrolyte and pH values began normalizing within 
2 days but mechanical ventilation was still required because 
hypophosphatemia was not alleviated (phosphate, 1.4 mg/dL). 
Phosphate replacement was increased to achieve a 5.7 mEq/kg/
day phosphorus rate. Fluid replacement with potassium and 
phosphate, and continuous intravenous insulin administration 
was maintained until laboratory findings were normal. On the 
third day, the patient’s vital signs were stable, self-respiration 
was recovered, arterial blood gas levels were normal (pH, 7.39; 
PCO2, 25.2 mmHg; PO2, 139.3 mmHg; HCO3, 15.6 mmol/L), 
and plasma phosphate had risen (3.5 mg/dL). Weaning from 
inotropic and ventilator supports was possible. The patient 
was transferred to the general ward the next day. On the fourth 
day of hospitalization, oral feeding and multiple subcutaneous 
insulin injections were started and phosphate supplementation 
was stopped. An electroencephalogram showed no epileptiform 
discharges or slow waves. The patient was discharged on day 10 
Table 1. Laboratory finding during admission
Variable Initial 2 hr 4 hr* 7 hr 11 hr 13 hr 16 hr† 18 hr 2 days 3 days
Glucose (70–110 mg/dL) 569 521 517 416 400 417 375 321 352 241
pH value (7.35–7.45) 6.92 7.03 7.05 7.07 7.09 7.13 6.80 7.18 7.28 7.39
Bicarbonate (21–28 mmol/L) 5.6 4.2 6.7 5.2 7.2 9.0 14.6 8.8 11.3 15.6
Sodium (135–145 mmol/L) 125 122 129 123 131 135 138 136 139 139
Corrected sodium (mmol/L) 133 129 136 128 136 140 142 140 143 141
Potassium (3.5–5.5 mmol/L) 3.2 3.6 3.2 4.3 3.0 2.6 2.8 3.4 2.8 5.1
Phosphate (3.9–5.8 mg/dL) 2.1 - 1.2 - - - 0.4 0.8 1.4 3.5
Calcium (8.8–10.8 mg/dL) 7.6 - 7.6 7.9 - - 9.2 9.0 8.0 6.9
Magnesium (0.75–1.2 mmol/L) - - - 0.7 - - - 0.75 - 0.5
Albumin (3.8–5.4 g/dL) 2.9 - 2.5 - - - 2.6 2.6 2.5 2.4
*After return of spontaneous circulation. †Respiratory failure.
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with no neurologic complications. The patient was followed up 
regularly. No neurologic complications or respiratory problems 
were noted, and the patient did not require further phosphate 
supplementation.  
 This study approval and informed consent were waived by 
the Institutional Review Board of Severance Hospital.
Discussion
This case describes a patient who survived cardiac arrest and 
subsequent respiratory failure due to severe hypophosphatemia 
during treatment of DKA. The pathophysiologic mechanisms 
involved in the development of hypophosphatemia in DKA 
include osmotic diuresis, which is caused by glycosuria and 
results in urinary phosphate excretion, and metabolic acidosis, 
which shifts phosphate into the extracellular compartment. 
Hypophosphatemia may be worsened during treatment of DKA 
because insulin causes a shift of phosphate into the cellular 
compartment and fluid replacement dilutes the phosphate 
concentration.1) These factors frequently lead to mild to mode-
rate hypophosphatemia in DKA patients. 
Severe hypophosphatemia causes the depletion of erythrocyte 
2,3-diphosphoglycerate, which promotes impairment of oxygen 
delivery to peripheral tissues. The depletion of high-energy 
phosphate compounds in muscles leads to muscle weakness and 
rhabdomyolysis, dysrhythmias, myocardial dysfunction, and 
neurologic symptoms like seizures.6,7) However, hypophospha-
temia usually does not cause clinically significant symptoms 
and is acute and self-limited. Therefore, phosphate replacement 
in DKA treatment has been controversial, with prospective 
studies showing no clinical benefit.2,3,8) Current guideline does 
not recommend routine phosphate replacement.5) However, 
severe hypophosphatemia (<1 mg/dL) even in the absence of 
symptoms, or hypophosphatemia associated with metabolic 
encephalopathy, impaired myocardial contractibility, respiratory 
failure, muscle weakness, or rhabdomyolysis should be treated.5) 
Cerebral edema should be taken into consideration in the 
differential diagnosis because the presented symptoms were 
difficult to distinguish from hypophosphatemia. The patient 
in this case presented with symptoms and signs suggesting 
cerebral edema, such as aggravated drowsiness, slowing of heart 
rate, and desaturation 4 hours after DKA treatment. However, 
brain CT scans at 2 different times revealed no abnormalities. 
Although there was gradual improvement in the patient's 
clinical condition after administration of treatment for DKA 
and cerebral edema, respiratory failure necessitating intubation 
developed within 16 hours. Respiratory failure in DKA can 
be caused by electrolyte imbalance (low levels of potassium, 
magnesium, and phosphate), cerebral edema, pulmonary 
edema, and infection. We considered severe hypophosphatemia 
as one of the important reasons for respiratory failure in this 
case because laboratory findings showed an initial abrupt 
decrease in phosphate level (from 2.1 to 0.4 mg/dL) followed 
by symptom improvement after phosphate repletion treatment. 
The normal brain CT scan findings support the hypothesis 
that hypophosphatemia was the cause of  the respiratory 
complication. Previous case reports demonstrated that hypo-
phosphatemia in DKA can be associated with respiratory 
failure,9-11) cardiac arrest,12) or seizure13) encephalopathy,14) or 
rhabdomyolysis.15) 
Among the electrolytes that are monitored during DKA 
management, phosphate is easily overlooked. According to 
DKA protocol, potassium is recommended to be replaced with 
a concentration of 20 mmol/L as form of either potassium 
phosphate with potassium chloride or potassium acetate.5,16) 
By replacing with potassium phosphate, phosphorus is also 
replaced. Although phosphorus is replaced simultaneously, 
the serum level of phosphate should require close monitoring. 
Especially, if the serum phosphate level is low or in the lower 
limit of normal range, phosphorus should be replaced more 
sufficiently. Severe hypophosphatemia in patients undergoing 
DKA treatment is rare but results in severe, though preventable, 
consequences. Although insulin and fluid replacement are the 
most important components of DKA treatment, early diagnosis 
and correction of electrolyte and blood chemistry imbalances 
should also be emphasized.
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